SCHEMBL10198285

SCHEMBL10198285

CCC1CCC(c2ccc(-c3ccc4c(c3)CCN4C(=O)Nc3cccc(C(F)(F)F)c3)cc2)CC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 11/20 0.65
RIPK1 Q13546 1/20 0.52
HTR2A P28223 3/20 0.49
HTR2C P28335 3/20 0.49
SOAT2 O75908 3/20 0.47
SLC2A1 P11166 1/20 0.46
LMNA P02545 2/20 0.46
MAPT P10636 1/20 0.46
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
PKM P14618 1/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HTR2B P41595 1/20 0.45
GRIN2B Q13224 1/20 0.44
CYP2C9 P11712 1/20 0.44
SOAT1 P35610 1/20 0.44
DGAT2 Q96PD7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL410375 0.91 DGAT1 (0.79) DGAT1RIPK1SOAT2CYP2C9SOAT1
SCHEMBL410376 0.91 DGAT1 (0.79) DGAT1RIPK1SOAT2CYP2C9SOAT1
SCHEMBL10198266 0.89 DGAT1 (0.68) DGAT1HTR2AHTR2CSOAT2SMN1; SMN2
SCHEMBL13190486 0.89 DGAT1 (0.60) DGAT1RIPK1HTR2AHTR2CSLC2A1
SCHEMBL10198278 0.88 DGAT1 (0.69) DGAT1HTR2AHTR2CSOAT2MAPT
SCHEMBL10198271 0.88 DGAT1 (0.82) DGAT1HTR2AHTR2CSOAT2PKM
SCHEMBL10198290 0.87 DGAT1 (0.68) DGAT1HTR2AHTR2CSOAT2CYP2C9
SCHEMBL10198264 0.84 DGAT1 (0.64) DGAT1HTR2AHTR2CSOAT2MAPT
SCHEMBL10198276 0.84 DGAT1 (0.68) DGAT1HTR2AHTR2CSOAT2HTR2B
SCHEMBL10198281 0.84 DGAT1 (0.66) DGAT1HTR2AHTR2CSOAT2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE SCHERING CORPORATION (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022057-A1 BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYGLYCEROL ACYLTRANSFERASE DGAT2, DGAT1, LCAT DGAT1 2/4885RIPK1 1435/4885HTR2A 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.